Home Cart Sign in  
Chemical Structure| 756525-99-2 Chemical Structure| 756525-99-2
Chemical Structure| 756525-99-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mal-amido-PEG4-NHS is a PEGn linker for antibody-drug-conjugation (ADC).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mal-amido-PEG4-NHS ester

CAS No. :756525-99-2
Formula : C22H31N3O11
M.W : 513.50
SMILES Code : O=C(ON1C(CCC1=O)=O)CCOCCOCCOCCOCCNC(CCN2C(C=CC2=O)=O)=O
MDL No. :MFCD11041113
InChI Key :XSRYGQJQNPJNKZ-UHFFFAOYSA-N
Pubchem ID :51340950

Safety of Mal-amido-PEG4-NHS ester

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P332+P313-P337+P313-P362-P403+P233-P405-P501

Application In Synthesis of Mal-amido-PEG4-NHS ester

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 756525-99-2 ]

[ 756525-99-2 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 6066-82-6 ]
  • [ 1263045-16-4 ]
  • [ 756525-99-2 ]
YieldReaction ConditionsOperation in experiment
0.109 g With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; Referring to the scheme of synthesis of Compound O, β-alanine was treated with maleic anhydride in DMF and the acid so obtained was reacted with N-hydroxysuccinimide (NHS) under DCC coupling to give NHS-ester. The BOC protective group in commercially available t-blc-N-amido-dPEG4-acid was removed by treatment with TFA to give the TFA salt of the amine, which was reacted with previously synthesized NHS ester. The carboxylic acid so obtained was isolated and was coupled with N-hydroxysuccinimide using EDCI to furnish NHS ester Compound O.
0.109 g With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; Synthesis of linker-drugReferring to the scheme of synthesis of Compound O, β-alanine was treated with maleic anhydride in DMF and the acid so obtained was reacted with N-hydroxysuccinimide (NHS) under DCC coupling to give NHS-ester. The BOC protective group in commercially available t-boc-N-amido-dPEG4-acid was removed by treatment with TFA to give the TFA salt of the amine, which was reacted with previously synthesized NHS ester. The carboxylic acid so obtained was isolated and was coupled with N-hydroxysuccinimide using EDCI to furnish NHS ester Compound O.
0.109g With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; [0277] Referring to the scheme of synthesis of Compound O, β-alanine was treated with maleic anhydride in DMF and the acid so obtained was reacted with N-hydroxysuccinimide (NHS) under DCC coupling to give NHS-ester. The BOC protective group in commercially available t-boc-N-amido-dPEG4-acid was removed by treatment with TFA to give the TFA salt of the amine, which was reacted with previously synthesized NHS ester. The carboxylic acid so obtained was isolated and was coupled with N-hydroxysuccinimide using EDCI to furnish NHS ester Compound O.
330 mg With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 2h; The product 4-11 (1.0 g, 2.4 mmol) obtained in the previous step and EDC-HCl (0.55 g, 2.88 mmol) were dissolved in 25 mL DCM, HOSu (0.33 g, 2.88 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. 50 mL water was added, the mixture was then extracted with EtOAc for 3 times (50 mL×3). The organic phases were combined, washed with saturated brine for 3 times (50 mL×3), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by prep-HPLC to give 330 mg product as colorless oil, yield 27%. LCMS (ESI) m/z 514.2 (M+H)+.

  • 2
  • [ 756525-99-2 ]
  • [ 1115-74-8 ]
  • N-[19-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-7-oxo-4,7,10,13-tetraoxa-16-azanonadecan-1-oyl]-L-valyl-L-alanine [ No CAS ]
YieldReaction ConditionsOperation in experiment
With triethylamine; N-[19-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-7-oxo-4,7,10,13-tetraoxa-16-azanonadecan-1-oyl]-<strong>[1115-74-8]L-valyl-L-alanine</strong> 73.3 mg (0.39 mmol) of <strong>[1115-74-8]L-valyl-L-alanine</strong> were dissolved in 7.0 ml of DMF, and 200.0 mg (0.39 mmol) of 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-{15-[(2,5-dioxopyrrolidin-1-yl)oxy]-15-oxo-3,6,9,12-tetraoxapentadec-1-yl}propanamide and 78.8 mg (0.78 mmol) of triethylamine were added. The reaction mixture was stirred at RT overnight. The reaction mixture was purified directly by preparative RP-HPLC (column: Reprosil 250*30; 10mu, flow rate: 50 ml/min, MeCN/water). The solvents were evaporated under reduced pressure and the residue was dried under high vacuum. This gave 103.3 mg (45% of theory) of the title compound. LC-MS (Method 1): Rt=0.58 min; MS (ESIpos): m/z=587 [M+H]+.
 

Historical Records

Categories